^^^ji^j j\ t u rt 3

(Special Access Scheme)

2563
 62Z-UZ-L^0
BULflB
rsLt,BSBiiBMSngss,fi,BitBij,u^n,n,.^unnuL(iuen
aeLW.e.n,1lMi
^tjA nnuR
un.Bitnsj.1 ^t.unsti^'Biij.LULSi.w.i^s.RE.Lun^^rtn^t.riim (uanraumjiisB) s
S.i^t.P'S'^ULBsBii (ntuirt^ (•uisp.ttB ^lulbbri RBwrtiinenauisii^ii.Raun]jrtriiic.rvri
JAlb
KLt.BjtfiritLJJLt.aW
Lr
n,Ln.nwLibib[jK&|rtLLun.|ji
•mm1

•smucy2

3
5

5 (^frnrinhsvmO8

8
9
o unainJBffs9
O ui^ivnaini'j'Ll'j^iia?^9

nTsHuTunmimyBTiM 5 (^^^t'iiinauan)n
o u.n^a'ufm-^ vilaiia'u^^'un (•a^acu^^ivnw'U"a^Ii5Fiasi^^W'u)n
O un^isla^mi ('ii'5alul5'3i,vnwu^a<iI'3fifjSji^w^vi^)11

my'sn (Cannabis)12

14
ouuu'U'uvin'ihsT^wibe15

Oll'UinJ'jsiS'Ufiaifnvifn^^a'UVimj (The Pittsburgh Sleep Quality Index : PSQI)16

ouu^'UisiiihH^mjfmjjil-M aims uaspmuli^a^iyihei20

ou.miaauEnjj EQ-5D-5L (fjfu/n^i^ia^'usiii^Tw)22

Oli^'Utl^^i.S'U Psoriasis Area and Severity Index (PASI)24
OnumbsiHu Eczema area and severity index (EASI)25

OauuaaumuR^^vi^^^^i'LbEi'bfl&bviw Dermatology Life Quality Index (DLQI)27

 eaudE daais qRU4s,iuR|Ri!,R]sE.p,r|Bi,G retuBBrt oi-S'2 ^sunft. 3H1 s^il 0,rbhrbr
DH1 IXRM,M3RRULBUGR 6LfU,lUl.BllAlS,.rULU U^\ LBU]pLllR3ymtLriLI3B.]iLrtBHl^^
9^,Tirtixuf3iBniAUirt[.RUBs-urtt.E, craui aaD
-g-AxojpAq-d)-^ ^auoAjEaojpAqip SB 11 suoAje^ '(auiAijEsiqeuuE^ojpAquE sbh
aujida SB11 unapaqj) sprauadjajifl pit.aiiinriULt^B^nt.p^]> sspioja^s SB11
'sppuoAEy 'sppiE^is awa^ tQSD sbti 3Hl"g9 UTiB^ijjri^BBaib
10|4iqEUUED '(USD) louiqeuuEa '(qaD) piaADiqeuuED '(ga3) uiosiaiqEuuea '(ONa^) loipouiqEuusa '(
loipiqEuuED 'OaD) suaujojqaiqeuuEa '(^8D) lOjaBiqEuusa 'OHi-g9) lou|qEuueaojpAqej}a^ g -suej;-(-)
'OHl-^9) lou|qEUUEaojpAqejia;-.g -suej;-(-) uil^^ ma, 01 ^^as^naBB)} \&h% 0^1 sprouiqeuuEocqAqd
b aMtit,BLt.aM,(nsBSE.n|iiAu^iLU
W t.L|M,saartLn
r\\ nw ule, bb LM,^iLH.ibua^B Liiiburi^
ULrt
9-e sbbbl) au 17
ataLB ^BH 6 LtUUBa (6'S2 SBI3B3) BB^ 62 flCJlLB BB^ 9"t7 SB^^L B^^^Bt-B^ (6'85 ^BBB3) nU 99
bbu -i sBaq su ^BauLaamLD.ibuLriLB^Lni!.at.B a^LBrtL^ (9'si sbbb^) au zz ac,uiB ^sy
(8'S2 SBBB3) au 8 atatB Ut-ia^LULBaBU SULrtt'B^B^ (ZZV SB
au^rt^aBa) ruas.LssBiiB'^uiBausaM.aB^iquLBLaui.p.^riuB s ^UlfbunrsLaira LBa^rau^ 3uaiur(3^BLi3s3M,LBi
BLaLBli^^BMULBKBb9]_B^BBBflKLt.USBTIBMgllgStp,rUaLlirjguBBliBLt 69X naMlLBa'jSBVI BLt 9S
s
1.iwaia^fju vwwjEjna^^. imyiPiuja^T,™ fre^fYif^nnrcMH'HYifliiasH'ilYiej. n^-jiwn : T^ivSuwtms'u, 2522.

2.fijjmj vmni at aaBan. m^^vil^^umm^iviEiuwiilviEj. lansniib^naijn'natJijj ivimnt^n n miWn^in

" a^tan^jjm^UYivieiiwiAvimiasmmyiYiEjvrai,aan •5svriiwi 29-30 iiraiau 2562

3.^fTafiEittflj ^^iTuirn uaswiruM ^^iilHtrquviti. mijjfwL^nmfitnmjwannj'in.

^vianrraFi^ n mYlwTtytnl'un'nuyiYitiiiHiilYitr ^l^afTSjjmiavivimiwulvia

iwi 29-30 luviEm 2562 w I^ii'siivii.mi'ii.a^^.

4.WHO Expert Committee on Drug Dependence Pre-Review. Cannabis plant and cannabis resin
Section 1: Chemistry. 2018. Available from: https://www.who.int/medicines/access/controlled-
substances/Sectionl.CannabisPlant.Chemistry.pdf?iia=l

5.Audu BS, Ofojekwu PC, Ujah A, Ajima MNO. Phytochemical, proximate composition, amino acid
profile and characterization of Marijuana {Cannabis sativa L). The Journal of
Phytophamnacology. 2014; 3(1): 35-43)
6.Natasha RR, David JR, Ethan BR. Cannabis Roots: A Traditional Therapy with Future Potential for
Treating Inflammation and Pain. Cannabis and Cannabinoid Research Volume 2.1, 2017. DOI:
10.1089/can.2017.0028.
7.Antonisamy P, Duraipandiyan V, Ignacimuthu S, et al. Anti-diarrhoeal activity of friedelin isolated
from Azima tetracantha Lam. in Wistar rats. South Ind J Biol Sci. 2015;l:34-37.
8.The Michigan Medical Marijuana Association. Cannabis Study: Full-Spectrum Cannabis Extracts
More Medically Effective Than CBD Alone. Available from:
https://www.michiganmedica lmarijuana.org/topic/49422-cannabis-study-full-spectrum-cannabis-
extracts-more-medically-effective-than-cbd-alone/)

9.Jaseena E, Pankaj G, Kalpna G. The Analgesic Potential of Cannabinoids. J Opioid Manag. 2009 ;

5(6): 341-357
10.Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and
cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin
Psychopharmacol. 2004 Jun;24(3):305-13.
11.Bharati P.Miodrag GR, David WC. Proof of concept trial of dronabinol in obstructive sleep
apnea. Frontiers in Psychiatry, doi: 10.3389/fpsyt.2013.00001
12.United States Patent Aplication Publication Cannabis-based extracts and topical formulations
for use in skin disorders. Available from:
https://patentimages.storage.googleapis.com/69/3e/ea/lacb93b735c9fc/US20180042890Al.pdf
 •tfaniwua
iltuicuaTniwiroa^wM^^ Immj 15% V/W

ai^niaa^aj'^'Banfl'i'a dpiaWyi^aau GT) nauainJisnau •3SOTJ 1 = liivtU

•ssotj 2 = milmnnnimJaBaiiH
i^^sHaauiaaiaai^a Detection limit 0.05 mg/kg

mTUmilawQEiTa^xviiin^

- mivm (As); ppm liiirm 10 ^huiuaTushu (ppm)

- asm (Pb); ppm Uiinu 6 a^ultjaTuaTU (ppm)
- UfiaUJEJSJ (Cd); ppm Immi 4.1 aTuluaTuaTU (ppm)
- tbavi (Hg); ppm liiinw 2 aTuluaTuaTu (ppm)

- Total Aerobic Microbial Count/g (ml) < 105 CFU / g (ml)

- Total Combined Yeasts and Molds Count / g (ml) < 104 CFU / g (ml)
- Total Coliform < 103 CFU / g (ml)
- Bile-Tolerant Gram-Negative Bacteria / g (ml) < 102 CFU / g (ml)
- Escherichia coli / g (ml)
- Salmonella spp. / g (ml) aa-^iiwu
 iMa vanitnjn
5 ml 10%

imam^ inauninajj ^nua^ (hvianaSnutJij Dropper

a^ wua^ anan^^^

anwusnisfnw tiaiiviaila

H 3aiwu
nan namovre^i
rinfmumnuiiu (g/cm3) ffiliivi^TuaTta^^w'un'^^n^aiSial^fu
fhfmimik (cps.) autyn^waeiuaT f^^^a^uTs^sijHil^)

ivauUR^^lieraiu (total aerobic bacteria) <2xlO2 CFU/ml

Sarfuasn (Yeast and mold) <2xlO' CFU/ml
nTstlntilan^'jala'ws'M'un*

an^vitj (As) liiinti 10 aTutuainaTu (ppm)

wsn^ (Pb) Iiiinn 6 ehuliifhtiaTU (ppm)
^a^iSaw (Cd) liiifvu 4.1 a^nlnaTushvi (ppm)
tl^avi (Hg) liiinn 2 aTulnanna^u (ppm)

i^ aria^ia l^uri
Staphylococcus aureus. (CFU/ml)
Salmonella spp. (CFU/ml) ^ailiivin
Clostridium spp. (CFU/ml)

Escherichia coll (CFU/ml)

•Uisncuani^'iflnj thc uas CBD ff^tjiviiTuHi (as^nnnm^^iii^iflaUfu

ansynnwa^iiia^ ^asau^^ats'ua'il^)
 iMa tfamviii^
•UlinfnTUTsa 30 ml + 10%
tma^W in^aajJViaia^nTOCi HDPE fltJ^inaa^awtl^ia^vi
•Uintn^fl^nviaia^niiiHanaantlaaEj

anwusniafnw na-aivia^la

1 aanwu

nati namawsiif]

riirminnnuiiu (g/cm3) ^jiiTsnaH-i^as^'iLU'umi^i^aiAiaWYua'uiijn^

fhfrcijivm^ (cps.) ^a^ua^ a-^^Kaiiniais'Ufi^l^)

rosuumiiiBrHi (total aerobic <2xlO2 CFU/ml

bacteria)

aaauasn (Yeast and mold) <2xlO' CFU/ml

i^fariaT^A l^uri
Staphylococcus aureus. (CFU/ml)
Salmonella spp. (CFU/ml) ^a^liivnj
Clostridium spp. (CFU/ml)
Escherichia coli. (CFU/ml)
tUsnsuaTs^'imij THC uas cbd ^ljivmafi'i^^^^iiu'Ufn^^i'ji^i^a'lafua'uqjiKi

wa^^a^ ?^^sia^uninis;tjfiiU)
 ri|J1 UBM, Z aBbU
nx.su> ^ru 03 nyire|k^&Minn
UIBM, 3 SBbSU niittM,lLI3BLniin,||^pMnglS.r;SB11!,LULeitLBBBLULfe flfc^rt^LULBULM, (I
LB.R3U
su s it-uuitt
y iwre aw grr|in.BM.nBntLUiiiLurobjjiit.[iftn.^ j: n.Bnn,BnM,]iBE,ji ???
(lOSd) x^pui
^ITlLUULU^BtUflLMStUBt.MrilJLn.M'nLBl^BtU ^
LBtin^i '9
nt ox-i t- i sniiLun]B'i^'|iri -s
03T re&nras nsmin^riQ 'b
i
'
'3
(bLBbB^rt^ UBBnUUB) ^LBSBItLtULW,bLBLItl,a,ii3ybBli LbLliSnt-B^ri ';
hbmilubgrko
^SB 3 at^artin S
rt|UOS ^mmfeiygmsBnuB b
rt^u OS
rt^uos LaKjynujaBiinMLB 3
rtuios Lft^^UULS. X
LBUn^LR LB^B RBIB
n a
Bt.^aEUSS.ri
ft*
ttBMbS.fl.
 at.su> ^ra^ 03 ayirt
SB^.W nilttM.ILB^Lail.aiflM.^BMnrtiSJ.f^SBll^LULeitLliS^^S.LULt ^^BIt^tULEULM, (I
tea t^u nuirq
a ^ sent, araw, 3 n.i|)r8|iLfiBLaii o
Ltuui,rtHB.ian,iiwLp,r{i.[.B!,ujiert ea : (
aran, 3 set^a ^BaBLBaLaii,a^n.M,^Mnais^p,sBiiJ.LULErti,BaatLUUL& au,a^LULBULM, (3
ma z ztss^yutfinBbirtMiL^iMtiiLrtu^ nMtaxiit^iLUintiuwLamiu ••
i&ibunrtia
rt it O
tu 6-^a 3 seat. aBM, z a^reHiBBLan o
aai fiByirciriLLULsrjflUM,RSBTi I
sw/i Laaat-fiya tfU^Bes^n t.sgiM.jwi|}iurts5fti|t.fiii,ui.Bjt aa as.um'^SRE.aat.riJ.LULSLM.it.j.a : s^sfxaeyn ??
^BU 3 SBE-^U ^^BBBLBBiaHRfM]iBran(|lSS!^n.SBTI.LULBrtlBBaLUULfc aHE^LULEULM. (3
aon 3|p]if^
O
n,
stw 6^a z seat, e^n 3 aa^tiLBaLan o
3UU/S>| 0S'8I LLUBBa
sseiAi Apoa) ra^uet-aaftaia sa jAfuuiLLUBBaunnLa^B^iXMa^: ^LHLeftJ4EiBt.B. j
 ,B^[iM.IASW]3UGBIAL
|% 5^ ixuusraiGiAeaah, z
BLS.^n,Bt'l3BlM,n,L6-LW.B^M, BU.UB6-SJ.Win,Ut.raU1B^M, SfUdL^nLB ^OJ.n.Lt'LW.IAM '
priMirmfBBM) ^
^-BU)uuiAU3ai3M,ti.uc-riM.iiLi<)SBii
i
OT
 nBBBmsmse'm.uin.Biuuc.'it.iuiArtuA
BBBm
1 f
f ^"
ttBMntertfUMm/isgM) ru,Bfi]il.i*|>r\Bus
LMuirut.imrtLuin^p nct
^a sent. E,LULB^w.nMrat.i^n,LW.: tra^Lnu, o
Rt.UirtLt.nfel.LULB[tseil ^ylSB|tEiW (.LlgBl^rjRBTlLtlH
S MlLB.fUUnjtLn^eiirUBIAE.e,B
^^ '9
nt ox-l j^ujm p.^etUM.srtrwtLtittgi sn
6-tt]_t,B, i LBtiniji ^RftiaftiL^^B ozi n&
U^UUSBflBjm^BB^BUglJ^l^BLndBBB '
^JATIIA^.l^ Z
BsBttttBLjAtLBLttLftfeytBd ^tL^ntBLn 't
UBHELUBUtEEU
^BZ LUXNUttltl g
tt^u g tJATIMATH-HlbyUBB
rttuos MATiLftibyn.^
rttu og LftibunLIJSBTlnMLB z
(ttU OS LRfbyuut X
LBuniALn LI3U^ nBLB
UBBltLIABIAIMltLUSBllBIA^M'nBIAM.'ntLUttS.U rtBMtLfX
g c-jA
XT
 (3LE,^anet-i3^iiAn,L6-i,iietM, BUE.UE^Ge.uirujc.GumL&'iiABWit snuuwiLBiinjut.Br^xji rtgt-t,c-^,^LW.t^e (ox)
^irux rtLiu^ rtuxui-ri nn run l(3m,hs.lulgjiulh (6)
i(8)
[fl| (i)
M I. nBM&^LIASIAbUBBj^Lrie^lAI^LBStp^ltBSSULRBt.BlAUttLUn,tMin.L]AULH (9)
^tti, (s)
ami rauot^L^GpntLBU ^ufiyMtun^iG^LM. jgtMtu rseniji ^6ijjB^n^rtLt.yjA^iuiLB(^M,ri
U[t1i (t)
frii (e)
^(z)
LftRjUJjHBUMgMn^nBRBU8tf,LBaBTILftfi3iyjATIB1ljfin'lft]>rtU^ (I)
l>t.SS.S.t.BGR. flGBlLB '
S.LUgri^fl^8M.UL(!iflBBaiAE,LUBMrjriBLtllALJijAI*njyMyM
'X
GB RLS.IA
MusstpiBiA^riMiiBa^Ti /Ba'iriMiiBiA^'nuL6B^figBtLU8B'nBft8iirx^BiiL6muirw'j /i nniRuuiu
ULG
fia^yiStRBMR|ltGBLMM,Lll^i LftRjUft^Ba^LRUttLULlX ^UBS^flBIA^RMIlBl^Hli /Blqn.MTirMM.llM.^BimG
(A^BiruiListp.tj^L
Kai I. na ? |j 8T LLULjs^i.8 ?
(rtua(n,GaB^niAiiM)|jbigaBM.n/M,ri/rain q
(Bt[lM)(lBLELLBMRALfl/BLn, [] L61IALII
UMRG^IlARt,
(uujoj xussuo^ pauuojui)
Lftn3UBE.BLRU^^LUn,^ttBBnBLnaE16-aBflBgM1.lil
zx
 BU^
p
(e)
^^^yiCiLBIAt N3B1Kl,t.UUlfijU
SLMB1 5
SB11
sui^sxon^
'3U|qdjouj 'u is '31ozeuodo}S>| ' 'uuejjem
nn.1
't7
Bt^yuiot. (uo^e;iSe) BLt.se,un.t.s.u (uone;usijos!p) neae (s^sneN) B^ney (mnouu Ajo)
^JjlTIULfl (sjnssajd pooiq leououqe) guf^gujJBjnjBrtLty (Eipjs^ApEjq) Lftnwi&^^ (uopEUipjo-cn
ByttBttLLBBBI (SS3UIZZJP) SRt^flByap Uliy^ LB,ii3yft]jt,LUULIini^yyiliLBltC-BU1t-Ln.BM (II)
ET
 ULflMULl/
n
 rtu^^^^nru.
Uns^M>in.h^uRRus
BLTlft mm .Lna
^t.^ rtcnt^
•o
ads
UdDS) nv
(1O9S) XSV
aH'da
ma
^^iitp 'urutun,
IS^.1- ^LURL!,
^B
b is a^ o a^rt^ o ^^Bss^^^- ai^aLmi.eTirn\Ti(^E.
^lt^tLULB
UBt12(32 ""I "-" ^
hs^ nai o
re^ o itiMie/t
as^ re o BBl 0 ^8^11 ''W) eiB^uiLBAM
Ks g 0 P^.0 ^ML&J^fUK^
BIA^aM'liRttM.nE-UQOBgLSUU
SHRH1 0 SUJUU O S^ t3[l 0 ^S&^S|1LM19LB SWKBl 0 SMUt, 0 SBM|\ 0 UB JtnEtiL^ : (snjRUBItLB) riB|lL^1t)^S
j^,M,y^^y.sa "riftLB,S!,fVtM^IHBI NH
& feus sua. o ^Q^^1
jAf^
SI
 Btt^riMTlBllMII
B^B^^^ttrt^tLULE
BMSs^^^rrjiiuia
(flSigUJ)
unsnin-B^^tLu
(ru,aimt.f,e^[^3)
Bu^nMn^LK
B^UtM^OsL^tjaU
^LUBLS,
91
^stBGjMVM ^^ttsen RujA^^
nrtiKfi^
.rt\a^wi3^nn/mw^ t^Rirtvi g< lOSd
ljrirtT;3ni.iutuy[t t33Ltw g 5 ^sd
ISOd nnnsu
(^sCMCfc^ UbEjuilb ol^
witi.^t(ia^n3i
^ <>
(x^rxuid3jugj n
fi^rxyianuugc 9'6
^jjMptuu/Bis-6
awa^iiui vt
LdtGULWritf '6
SjufiLtuL^irijj^jijM.Bunij j-6
r^u B^suuiiniuBgiiu i MiHigyjBgiLru^u ore- re 89nytt.ULunjuu.j1
= ULItL^^JQd^I ^ CCWIt^SmiUlj(Jlt
1= BBRu^itix^^jjjrt o~ BBim!lj^ui[\idi
rwii^uv^i^^ryifiiuBEriuA '8
[= VXLWfi^/HW T> 0= BBlli^Byilt^
ucrij nfti ^Li^tuuByciiiuj
y^tuicmBarxBdnBrii.B^^aLic '9
z= ^ l- uirty
= ^dlBRt > = trdBfc 9S
I = ^IC^CJ^ Z'9 0 = crt^CB 2<
^K]ULi9t.merui|tuntn>.K|^M^ru.{3
= IJLn 09 < Z = ^Ld 09-0
I = jan o-9! 0 = ^en si >
aBdn^rianuiiym.*!
ljtriurout^crmi.aust.ij^euni.11 z
rttotu
9 ttLUUU S rtutuu f rtiuuw Citun^ z nutw T rtLUUU ruutn
: etmrtun-eft
NH
2iBn.tiy[ g tuuiF VM.rtu.utUM.tL
1 16 raiuwjl (lOSd : xspui ^^ner DC Mis MSjnq sq)
rw^neru m
 .,^

(The Pittsburgh Sleep Quality Index : PSQI)

WluFiafinnqfflnvram^imYiihimilYiti (aintytniM 5 ^^^ivmhsvn i
*>-u-uwi)fi:u-Ml^^i^
HN 99999

fhcnji inniu aaaou 1 aaanii 2 aaanp 3 aatny 4 Mia-m 5 annnu 6

(Unbt 1 laatmrhuin)
24 2.a. 63

l.floul^ciJYioiiiin^^ouauiiaoiiTun 22.00 u.

45tn .. ..2.
a^umthuauauwmj
< 15 unvi ^ 0
30-60 Una = 2
16-30 unvi ^ 1 ^
> 60 unvi = 3
3. ttaulvuyvmiiifnmjuaijnannUn 06.00 u.
1 —
4. tJnSvhtntmj'Wmjasmi'i'Uu
>7 ^nUn ^ 0 6-7 tnlun ^ l
5 vv. ... .2. J
5-6 ^nUin = 2 <5 tbU.i = 3 ^

^fiBnm^^tjaait'U
3
aim .1 a -2
Uaaaa =3 Uiaiaa =4

Uiaalmaa=o <1 a^n/aiianu =1 2

7. aouvan4i4tjaBiviattalijsEVTi4
m^vnnanstpaoti mil tiuda
2
Uiaaltiiaa ^0 <1 asn/aiJanu =1

1-2 afn/^\JanM -2 S3 afn/^njanw -3

2
Uinlu^^juniaa ^0 Eiiiijunianuaa ^1
uiiiljunaaaufln^ =2 i^uOruunjinn =3
9. vinu2t)tyvoinaimjmsuau ^iviTuanantjlu^^a 9.1 -9.10 n^wmaan^mat 1 aoiaanUuaas^a a^u

mJE^u'] 1 2 asn/^ijanii ^ 2 iiO^Mn ^3 atv^tjanu = 3

9.1 uauUMmjaatannitnuauUuao
3
30un^
9.2 aunanran/auiannnntlnw 3
9.3 auitinviavun 3
9.4 wnattaaaa 0
9.51a/ntu ^atat 0
9.6 S^nwuo-iiriuUJ 0
9.7 fflnfauiSuiiJ 1
9.8 ilusna 1
9.9 i^uMSBlJoaanuah 2
9.10 anwaau^ (Itbassij) Cnnunui^an '•

65UUU PQSI 17

PSQI s 5 viinapn uatuanauauMauvia Ilia

PSQI >5 nenaar ufi^rnauauwauliia

nnJstiiiu Wftnn

aaiuJa1fl The Pittsburgh Sleep Quality Index (PSQI) 1B asoumj ^ilJsailll^^vfm} uasofnj auTO^aa
 19

nu^U^sii^^flW^^inmmauws'uamiii ^^^iuJaOTin The Pittsburgh Sleep Quality Index (PSQI)

I^^Ej wsTimi ^bibsjjt^virm uam^cy

j ainflntnuwviija 9 ifa ^faawgittamuwH 7 a-amhsnau

siiiJri ^u
a^mbsnauvi 1 suwtia 5
j WwaTjjmsttimifa 2 na^ 9.1

^ 0wa^i^aKunu 1-2 = 1

= 2wa^ufiKiimi 5-6 = 3

84mJn8tiyi 4 iJ^^

^mtnEuainnaimuaii (ifa l) p^^^Bnanwittiaii (iia 3) xioo%

>85% = 075-84% = 1

65-74% = 2<65% = 3
5 nTsittmufn^uBvivali WwaTiumanjiifB 9.2-9.10 iviimj

= 0waTiuatiimi 1-9 = l

10-18 = 2wan^^siwvi 19-27 = 3

a^mhsnauvi 6 (mWaiuaumnj T'Snasuuu^s 6

84Bil^snBiivi 7 wan^svitjiBnT5iinnBn'5'5ii'l'unanna94T:u Wwa^iiflBimiiiia 7 aas 8

0wa^^flKuim 1-2 = 1

3-4 = 2Naiiufl^uu'u 5-6 = 3

7 a-jfiil^sinaittia-JiitJtJtJ^siiliiflnifnYimiuatJvimj a^j^s!vn'i^ 0-21 flKiiuvi nniw

5 flsiinii wna
5 f\^v.

Reference
1. nsiufti 50ijTO^^n uasifiu Ii4wnmaiM wrutflinrf.

43ra. (2550). Btu^nyim4uaijiimjua=misi!iirnii5rao4TO'4nrnin?fllulyiti™na4s nmn^iynannum.

2551n.B.^552(oCvjiilfl):71-85.
 20

t!a-injjana
HN
VAJ remjtmmba Patient's global assessment mnwntiB^mstJo^i
(Pain score) nTsthsiSuanrmtatiTHj^^iimiia^
duira l i^bu) (n^^)

• Pain score : T^^ Numeric Rating Scale (NRS)

• Patient's global assessment 5 mj

1 = very good 2 = good 3 = fair 4 = poor 5 = very poor

 dd 'fcXH 'fW l^^^a ^^L r quaumeaq asu>| sgumJBoa^o am
u| OEuappip o} ajEdwoo (pejpo jaSujS) -dV\IH P ^^D^^ '(000^) 'S 'EqBjSnuEJES>)v <$ "r 'Suoquoog : aauaja^ay
^xi. g ^ (t-ein^RL^rtt.ra^.i,ULBnmsj.f\e.LU) ^uauussssse -jeqoiS
: utu
aupipaiM ^o ^EJq^ Ieuoijen 'S'n 'uopEauqjui /Soiouqoajoig joj jajua^
'adEo^pai^ 'aupipa^ p ^jEjqn ieuojjbn 'sti 'uogBouopi /Sopuijoapig joj japa^ ibuoijen :aDJnos
tqui6eui| r-
u|disjoM I
III
O169S*EZIO
IIIIII
I(SON) a|B3S ""^'M |B^pa^"N 01-0 3MOOS NlVdj
BMBf^Ti^i-u
 dnojg /oo<ung s</g;o ^ou ^pafl e si mas-03 dnoig /oooi/g ZKK ® (^UL) pueneia
DBSUUUtMJ)OLtl41lt^8^BttUUtUetl.jmLJ
DULfllLpOLI.lllll^OtMIStt-UlJSt.UsJl.fmLJ
D
D
D
LtUlltgRLLH / BLtUUHLItLLM
O
?jmunLpLnLri8rt|LLULoaLWL|jrjkiLLULO]tL6mL.
C
D
U>RLIU1R|1LULO / BtpilMLLULO
D
O
?
([ic.iriniututyBu uunatuninuuty 'numuui 'oernnnn^ 'hulu np) Lf3tpH^iL_urtitusu
LUnLGLtlMLJ.
?ULRlLGGlGinGLLnG|lG^U LnnLGLLUll^LUiilQRL^lHL^
OILBUnLfllGmGGLGLIJGGlG^G^IIl LnnLGLLUn^Lblih^IflL61ML^^
OG
D
?
?
rubuih^gji^ig a RLJM^G^iiLULiaiu G^Lu:GGnn^
 dnaig /oQajng fl /o ^ein ape^ b a mos-03 <*><"9 /oO<""3 ^^0^ 9 (^i) P"B0U
rutttatuu mtumu
w^umiM ii/gJI
0 -n
9 -,
01 -=
S^ ^
az —
sc -3E-
OS
95 ^P
OS
S9
(U
09 Hr glruig^uilu
'UljUGIUftUrtllUftUt UGUGGMLI/ft^^ 1GGU1U Q
06 -^^- ni.iuGiuium.i.uiiu> UBljjtuu/ii tynuiu qq|,
96 :: '00^ ^5 0 U^lUGGIt^l
nuuGGUjtraiurtut
 24

Psoriasis Area and Severity Index (PASI)

nuYivitiiiwiAviij (tnunjunt^ivn 5 ^M

tlo-uiiiflna:
HN quvi wtbsum

^^ Score Body Total score

Erythema (E) Induration (1) Oesquamation (D) Sum Area score
Body\^ surface (sum x area score x
[0-4] [0-4] [0-4] (E+l+D) [0-6]
area body surface area)

Head (h) 0.1

Upper limb (u) 0.2

Trunk (t) 0.3

Lower limb (0 0.4

PASI score

Ttivi wthsiSu

\. Score Body Total score

Erythema (E) Induration (1) Desquamation (D) Sum Area score
Body^v surface (sum x area score x
[0-4] [0-4] [0-4] (E+l+D) [0-6]
area body surface area)

Head (h) 0.1

Upper limb (u) 0.2

Trunk (t) 0.3

Lower limb (I) 0.4

PASI score

TUB MlhtllfjU

^^ Score Body Totals

Erythema (E) Induration (1) Desquamation (D) Sum Area score
Body\^ surface (sum x area score x
[0-4] [0-4] [0-4] (E+l+D) [0-6]
area body surface area)

Head (h) 0.1

Upper limb (u) 0.2

Trunk (t) 0.3

Lower limb (I) 0.4

PASI score

• Erythema None Slight Moderate Severe Very

• Induration severe
• Desquamation

hTll^.]
• Area 30-50% 50-70% 70-90% 90-100%
0% <10% 10-30%

U(inn : umnhsiim Psoriasis Area and Severity Index (PASI) ^i^MW sinww'u (Psoriasis)
heiYlPllvit)

: http^/www.rcpt.org/index.php/news/2012-09-2^-09-26-20.html
 25

Eczema area and severity index (EASI)

^^i 5

tta-mjinqa: HN ^jihsiilu
^^ Score Erythema Induration/ Excoriation Ucheniflcation Severity Re^ion Multiplier Total score
(E) PopulationCI) (Ex) <O score sum Score (Severity score sum x
Body \^ [0-3] [0-3] [0-3] [0-3] 104]
x Multiplier)
• Head/neck (H) 0.1

• Upper Umb 0.2

(UU
• Trunk CT) 0.3

• Lover Umb (LL) 0.4

EASI score
tja-unua^t): HN oiivi ^flh^uiu
\^ Score Erythema Induration/ Excoriation Ucheniflcation Seventy Re^ion Multiplier Total score
(E) Population(l) (Ex) (L) score sum Score I Severity score sum x
[0-3] [0-3] [0-3] [0-3] Fteskxi score
Body N. [04]
x Multiplier)
• Head/neck (H) 0.1

• Upper Umb 0.2

(UL)
• Trunk <T) 0.3

• Lower Umb (LL) 0.4

EASI score

tfo-uiaaqa: HN Tliv! Hlhsuh)

\. Score Erythema Induration/ Excoriation Ucheniflcation Severity Region Multiplier Total score
(E) Population(l) (Ex) (L) score sum Score (Severity save sum x
[0-3] [0-3] [0-3] [0-3] Re^ion score
Body \^ [04]
x Multiplier)
• Head/neck (H) 0.1

• Upper Umb 0.2

(UL)
• Trunk CT) 0.3

• Lower Umb (LL) 0.4

EASI score

Severity score 0 1 2 3
• Erythema None/ Mild Moderate Severe
B Oedema/papulation clear
• Excoriation
• Ucheniflcation

Region score 0 1 2 3 4 5 6

• % involvement 0% 1-9% 10-29% 30-49% 50-69% 70-89% 90-100%

MtuiJlWin: uuuthsuhj Psoriasis Area and Severity Index (PASO ^uv)WMnTJ^UB^tfoftNiui2u'n(hwiJi(Atopic D

uns Determining EASI The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema
 26

• mmtJawa Eczema area and severity index (EASI)

EASI total score range from 0-72.

Reference: Leshem YA, HajarT, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score

tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172:1353-1357.
 27

Dermatology Life Quality Index (DLQI)

fr$EuiBTjflnfnjj^^tivhifi^a^^nEi V a^luiravn-JimiiB

n7a^
menu Tuft Tuft fufi
l. VH^^J^mmshwn ^nijeifmmi, Aj, thn vi1athfii3a^ Oinn(3) 0 um (3) 0um(3)
viHivnj^infiijarji^fi-ilfl 0 tlnunn^ (2) 0 tliunfn^^ (2) 0 tJiunBn (2)
o iSnuau (l) 0 i^nuaa (l) 0 ^inuati (1)
obiflimfo) 0 TiifllElEJ (0) oliiSiaa(0)
2. Tb^pTiJn'iwiphiiin wuw^u^nTvfafu^naua'iti, mflfrnu 0 inn (3) 0 inn (3) 0 inn (3)
iru^^ jnnuamfitwUi 0 ^nunm^ (2) 0 tl-njnn-H (2) 0 tliunan (2)
0 i^nuatJ (1) o i^n^ati (I) 0 i^nuatj (1)
oliiSiaa(O) 0 liiuiati (0) Olu'Si^ifO)
3. ^mefiJwmvtthwn Huw^vn^^iihWflnjiKJty^nTufmaamnn 0 inn (3) o inn (3) O inn (3)
ihuhJ^wiEWashifh, auairm ^a^uaa^u innuoEiiviEj^Ui 0 ihunfm (2) 0 lJiunnn (2) O TJ-runa-N (2)
0 iSnSsB (D 0 i^n^ati (1) 0 i^^uoti (1)
OliiSiaafO) OlliSlfiEJ(O) O liiSimi (0)
OliiSm-BiiflinfM O TiiSfmiJintnfa^ OUSflTBlAnfM
4. ih^W^mi f rlthijin wuwiwj^a^^flj ijHflnYUJefmL^an 0 inn (3) o inn (3) oinn(3)
0 thum^ (2) 0 xJiunan (2) 0 tJiuna-H (2)
0 iSnijBU (I) 0 L^n^aa (i) 0 i^nuatJ (1)
0 liiSiatj (0) O "UiSi^i (o) olii'Siaulo)
o "UiSn-n uintiToo^ OtiiSfnujintn-DBi olu'Sfmurfirrfw
5. li^jfj^niiviwiuiji wuetawJttKMflnj Sw^n^sviTjriafnwi o inn (3) O uin (3) 0 iJin (3)
tfafiu vrieria^^fmwluu'un'^ mnuatimtNlfi 0 \Jiuna"M (2) 0 IJIWKTM (2) O \J"iu na"M (2)
0 i^n^aa (1) 0 Jln^aa (l) 0 i^nuaa (1)
0 liiSiau (0) O iiiSmii (0) OlliSiaaW)
0 liiSrmiunEnf&) o^ftrmi^^fw oliffl^mu^tniw
6. riwMffi'iwiNimn Hu^hvnj^ilwfif^sYitJfflan'mEmnwi m^ 0 inn (3) O inn (3) 0 inn (3)
aanm^rno va-^ fu inuaEiifia^U 0 rJ-njnfn^ (2) O tliuna^ (2) 0 tJiunan (2)
o i^n^sa (D O i^nijBtj (l) O i^nuaa (1)
0 UiS^^cj (0) ob'SiaafO) 0 liiSiatj (0)
0 "UiSfmuintntB-J oliiSmiiJiniJTtiBfl 0 liiSmnJintnftN
7. ^^fU^nwiwnuin wusbwj^iiwfmitvffltutnfi^u mam^ oS OS OS
oliiS OlliS OlliS
OimiiKnfM OfiTnllnfM 0 fmuinBTOM

0 unn (3) 0 rm (3) 0 Bin (3)

rnnhrw n^^s mvfou innvemiit^fo 0 tJiumn^ (2) O il-nina-H (2) 0 iJiunan (2)
0 ^^nuaa (D o i^^nuflu (l) 0 i^nueti (1)
oliiSuiutO) oUSun(o) O lliSlBEl (0)
8.i^^^^Un-nWlrhian wuH^u^aiflajUm^^suvnWn'u 0 inn (3) O inn (3) o uin (3)
nma^ ^at^nS niainaauvi ^nnuaBifi^lfi
0 iSmjBU (1) O iSnSaa (l) O i^nuBB (l)
o liiS^cj (0) oluuiati^^)
0 liiSfmuiflait'a ^
9. li^^f'iJ^niiviH^uuT wuw^nin^TnHfltujJilty^ni'u nin! 0 inn (3) 0 inn (3) o urn (3)
mfiifuwuB inrnfotiLi^^ifi 0 ilium^ (2) O ihunan (2) 0 diuns-M (2)
0 i^nuau (1) 0 liinSati (l) 0 l^flUBB (1)
o liiSwti (o) O lu'Si^ti (0) 0 lliSlBB (0)
o liiSfniiiifiaifa^^ Oliifl^nwntntiei oliiSfinuLfumiei
10. li^^^iJanviviH'nmn nn^^hwElijHWiJE^rieWu^liuvnuri 0um(3) 0 inn (3) O uin (3)
ficu unntieamo^l^ ^Hi viMmlm^itJ^esi^ie^^uijiu, m7 OtJiunaii(2) Odiunfl-M(2) 0 ihunan (2)
0 i^nuaa (1) 0 i^^n^aa (l) 0 i^nuati (1)
fn^i^nlviiiian^n i^^^wu

olifflfmu^nfM OiiiSfmu?ltrrifB 4 0 liiSfmiuninftw

DLQI Score
n : uuwhsiSu Psoriasis Area and Severity Index (PASI)
ibn: httpy/www.rcpt.ors/index.php/news/2012-09-24-09-26'20.html
 28

DLQI score

0-1no effect at all on patient's life

2-5small effect on patient's life
6-10moderate effect on patient's life
11 - 20very large effect on patient's life
21-30extremely large effect on patient's life

Reference
1.Finlay AY and Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine
clinical use. Clin Exp Dermatol 1994; 19:210-216.

2.Basra MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007:

a comprehensive review of validation data and clinical results. BrJ Dermatol 2008; 159:997-1035.

3.Hongbo Y, Thomas CL, Harrison MA, Salek MS and Finlay AY. Translating the science of quality of life into

practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125:659-64.

: vwrw.dermatology.org.uk.